Clinical trials: Neoplasm, Oral
Chronic Lymphocytic Leukemia, Leukemia
Oral Valganciclovir Versus Valacyclovir
To determine if the rate of cytomegalovirus reactivation during treatment with alemtuzumab (Campath) is reduced by the use of valganciclovir prophylaxis.
- Trial name
- NCT00562770
- Testing
- Valganciclovir, Valacyclovir
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphobkastic Leukemia, Medication Adherence
The AYA Oncology Self-care Movement
This trial will test the impact of a social media intervention for improving oral chemotherapy adherence among adolescents and young adults (AYAs) with acute lymphoblastic leukemia.
- Trial name
- #AYAOSM (NCT07724652)
- Testing
- Educational Website, #AYAOSM
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Northwestern University
Advanced Solid Tumor, Metastatic Solid Tumor
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
- Trial name
- NCT06577987
- Testing
- CID-078 Monotherapy
- Where
- 10 sites in United States
- Volunteers
- 220 people
- Sponsor
- Circle Pharma
Leukoplakia, Periodontal Disease
Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR
In Phase II trials, treatment with ketorolac tromethamine oral rinse has been shown to block periodontal disease progression even in the absence of standard clinical intervention such as scaling and root planing which is…
- Trial name
- NCT00001698
- Testing
- Ketorolac Rinse
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasm
Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients
This is an open label expanded access protocol for the treatment of up to approximately 40 adult or pediatric (defined as age <18 years) patients with tumors harboring either a chromosomal translocation or activating mutation…
- Trial name
- NCT02473497
- Testing
- Crizotinib
- Where
- 17 sites in United States
- Sponsor
- Pfizer
Medulloblastoma, Ependymoma
Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma
It is an open multicentric phase I/II trial with axitinib (Inlyta®) and metronomic delivery of etoposide for children, adolescent and young adults (AYA) with refractory/ relapsing solid tumors.
- Trial name
- MEPENDAX (NCT06485908)
- Testing
- administration of axitinib in combination with etoposide
- Volunteers
- 40 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Carcinoma, Non-Small-Cell Lung
Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I Study
The study is designed for subjects whose cancer is too advanced and therefore cannot be operated with the goal of completely removing the cancer.
- Trial name
- NCT00256815
- Testing
- chemotherapy, Radiation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Clinical Oncology Research Associates
Prostate Cancer
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than once drug may kill more tumor cells.
- Trial name
- NCT00003717
- Testing
- estramustine phosphate sodium, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- St. Barnabas Medical Center
Hepatitis C
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
Compare Hepatiis C Virus (HCV) detection between oral squamous cell carcinoma (OSCC) and normal tissues, to determine the possible relationship between HCV and OSCC.
- Trial name
- NCT03109457
- Testing
- oral squamous cell carcinoma
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Polycystic Ovary Syndrome
Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy
Oral contraceptives are known to improve menstrual cycles and symptoms in PCOS, however may increase cholesterol. Metformin, a drug to improve insulin resistance, may benefit metabolic state.
- Trial name
- NCT00283816
- Testing
- Metformin, Oral Contraceptive Pill, Lifestyle Management Program
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Oral Mucositis
Laser Therapy Effect as Preventive Measure for Oral Mucositis in Children With Hematological Malignancies
Introduction: Among the most drastic complications of chemotherapy is oral mucositis(OM). It is a painful inflammatory, often ulcerative condition and may increase risk for systemic infections leading to prolonged hospital stays…
- Trial name
- NCT06267417
- Testing
- Laser therapy, Mock treatment
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Potentially Malignant Lesions, Oral Lichen Planus
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
The aim of this study is to evaluate salivary expression of lncRNA DQ786243 as a potential marker for diagnosis of oral potentially malignant lesions compared to normal controls and its effect on salivary expression of miRNA146a.
- Conditions
- Potentially Malignant Lesions, Oral Lichen Planus, Leukoplakia, Oral
- Trial name
- NCT05730855
- Testing
- Real-time Polymerase Chain Reaction technique
- Where
- Egypt
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Fayoum University
Solid Tumors, Neuroblastoma
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not…
- Conditions
- Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma
- Trial name
- NCT04337177
- Testing
- VAL-413, Temozolomide
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Valent Technologies, LLC
Refractory Solid Tumor, Hepatocellular Carcinoma
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent…
- Conditions
- Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor, Pediatric Cancer
- Trial name
- NCT05468359
- Testing
- Atezolizumab, Sorafenib, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- St. Jude Children's Research Hospital
Parotid Tumor
The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome
The aim of the study was to explore whether human acellular dermal matrix (ADM) implantation could prevent infraauricular depressed deformities and Frey's syndrome following total parotidectomy.
- Trial name
- NCT01414790
- Testing
- ADM
- Where
- China
- Volunteers
- 70 people
- Sponsor
- West China Hospital
Prostate Cancer, Urinary Incontinence
Prospective RCT on Post Prostatectomy Urine Leak
Objectives: Primary: Comparison of proportion of patient achieving continence between the four arms at 6 months. Secondary: Comparison of time to achieve continence between the four arms.
- Trial name
- NCT02367404
- Testing
- Duloxetine, Pelvic Floor Muscle Training
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Institut Mutualiste Montsouris
Urinary Catheters, Rectal Cancer
Tamsulosin for Early Catheter Removal After Rectal Cancer Surgery
This study aims to systematically evaluate the safety and efficacy of different early urinary catheter removal strategies following radical resection of mid-low rectal cancer.
- Conditions
- Urinary Catheters, Rectal Cancer, Urinary Retention
- Trial name
- NCT07346586
- Testing
- Tamsulosin group, 24-Hour Removal Group, 48-Hour Removal Group
- Where
- 2 sites in China
- Volunteers
- 1,545 people
- Sponsor
- The First Hospital of Jilin University
Esophageal Cancer, Head and Neck Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002951
- Testing
- fluorouracil, hydroxyurea, surgical procedure
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Chicago
Head and Neck Cancer, Oral Complications
Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
RATIONALE: Sargramostim may lessen symptoms of mucositis in patients receiving radiation therapy for head and neck cancer. It is not yet known if sargramostim is more effective than no treatment in reducing mucositis caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00008398
- Testing
- sargramostim, quality-of-life assessment, radiation therapy
- Where
- 236 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Acute Lymphocytic Leukemia
Effect of Oral Supplementation With a Fibre Enriched Paediatric Sip Feed For Children With Acute Lymphocytic Leukemia
This is a randomised, controlled, open-label intervention study. It is hypothesized that supplementation with a fibre enriched sip feed will improve the nutritional status, gut microbiota and quality of life (QOL) of children…
- Trial name
- NCT01600781
- Testing
- NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Children's Cancer Hospital Egypt 57357